Factor XIII deficiency is a rare but potentially life‐threatening bleeding disorder that disrupts the final stage of clot stabilisation. As a multifunctional transglutaminase, Factor XIII plays ...

Switching to extended half-life therapies for hemophilia enhances treatment adherence and reduces infusion frequency, despite ...

There are some private laboratories that conduct the factor assay test — required to identify the factor responsible for haemophilia — but they, too, are concentrated in Calcutta. Factors, or clotting ...

BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

Proactive prevention remains an effective and sustainable measure in combating dengue fever and reducing its impact on both ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

The 18-year-old student from Baker’s Rd, Gurranabraher, was rushed by ambulance to Cork University Hospital after becoming unwell at her home on the morning of June 10, 2024, just before she was due ...

Deadly and silent, thrombosis affects thousands of Australian women each year during pregnancy, postpartum, menopause or ...

The University of Colorado Anschutz Medical Campus will lead a groundbreaking national clinical trial-supported by a $29 million grant from Octapharma-to evaluate whether early replacement of ...

Willebrand disease (VWD) is considered the most common inherited bleeding disorder, even surpassing haemophilia A. Nevertheless, ...

Hemostasis Market Insight, Epidemiology and Market Forecast - 2032The hemostasis market is experiencing significant expansion, driven by inc ...